Literature DB >> 19943872

Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A.

C D Porada1, C Sanada, C R Long, J A Wood, J Desai, N Frederick, L Millsap, C Bormann, S L Menges, C Hanna, G Flores-Foxworth, T Shin, M E Westhusin, W Liu, H Glimp, E D Zanjani, J N Lozier, V Pliska, G Stranzinger, H Joerg, D C Kraemer, G Almeida-Porada.   

Abstract

BACKGROUND: Large animal models that accurately mimic human hemophilia A (HA) are in great demand for developing and testing novel therapies to treat HA.
OBJECTIVES: To re-establish a line of sheep exhibiting a spontaneous bleeding disorder closely mimicking severe human HA, fully characterize their clinical presentation, and define the molecular basis for disease. PATIENTS/
METHODS: Sequential reproductive manipulations were performed with cryopreserved semen from a deceased affected ram. The resultant animals were examined for hematologic parameters, clinical symptoms, and responsiveness to human FVIII (hFVIII). The full coding region of sheep FVIII mRNA was sequenced to identify the genetic lesion. RESULTS AND
CONCLUSIONS: The combined reproductive technologies yielded 36 carriers and 8 affected animals. The latter had almost non-existent levels of FVIII:C and extremely prolonged aPTT, with otherwise normal hematologic parameters. These animals exhibited bleeding from the umbilical cord, prolonged tail and nail cuticle bleeding time, and multiple episodes of severe spontaneous bleeding, including hemarthroses, muscle hematomas and hematuria, all of which responded to hFVIII. Inhibitors of hFVIII were detected in four treated animals, further establishing the preclinical value of this model. Sequencing identified a premature stop codon and frame-shift in exon 14, providing a molecular explanation for HA. Given the decades of experience using sheep to study both normal physiology and a wide array of diseases and the high homology between human and sheep FVIII, this new model will enable a better understanding of HA and facilitate the development and testing of novel treatments that can directly translate to HA patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19943872      PMCID: PMC2826196          DOI: 10.1111/j.1538-7836.2009.03697.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  43 in total

1.  Accuracy of FVIII: C assay by one-stage method can be improved using hemophilic plasma as diluent.

Authors:  S Cinotti; E Paladino; M Morfini
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

2.  Toward gene therapy for hemophilia A with novel adenoviral vectors: successes and limitations in canine models.

Authors:  V R Arruda
Journal:  J Thromb Haemost       Date:  2006-06       Impact factor: 5.824

3.  Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies.

Authors:  L Bi; R Sarkar; T Naas; A M Lawler; J Pain; S L Shumaker; V Bedian; H H Kazazian
Journal:  Blood       Date:  1996-11-01       Impact factor: 22.113

4.  Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease.

Authors:  P L Turecek; H Gritsch; G Richter; W Auer; L Pichler; H P Schwarz
Journal:  Thromb Haemost       Date:  1997-03       Impact factor: 5.249

5.  Cosegregation of a factor VIII microsatellite marker with mild hemophilia A in Golden Retriever dogs.

Authors:  Marjory B Brooks; Jennifer L Barnas; Jacqueline Fremont; Jharna Ray
Journal:  J Vet Intern Med       Date:  2005 Mar-Apr       Impact factor: 3.333

6.  Synovitis in a murine model of human factor VIII deficiency.

Authors:  N Hakobyan; T Kazarian; L A Valentino
Journal:  Haemophilia       Date:  2005-05       Impact factor: 4.287

Review 7.  Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients?

Authors:  K High
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

8.  Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A.

Authors:  L Bi; A M Lawler; S E Antonarakis; K A High; J D Gearhart; H H Kazazian
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

9.  Changes in longevity and causes of death among persons with hemophilia A.

Authors:  T L Chorba; R C Holman; T W Strine; M J Clarke; B L Evatt
Journal:  Am J Hematol       Date:  1994-02       Impact factor: 10.047

10.  Factor VIII in blood plasma of haemophilic sheep: analysis of clotting time-plasma dilution curves.

Authors:  S Neuenschwander; V Pliska
Journal:  Haemostasis       Date:  1994 Jan-Feb
View more
  29 in total

1.  A new mouse model for wound healing in hemophilia A.

Authors:  Guangwei Gao; Dhahiri Saidi Mashausi; Hema Negi; Dongsheng Li; Dawei Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.

Authors:  P M Zakas; K Vanijcharoenkarn; R C Markovitz; S L Meeks; C B Doering
Journal:  J Thromb Haemost       Date:  2014-11-11       Impact factor: 5.824

3.  Alternative strategies for gene therapy of hemophilia.

Authors:  Robert R Montgomery; Qizhen Shi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

Review 4.  Animal models of hemophilia.

Authors:  Denise E Sabatino; Timothy C Nichols; Elizabeth Merricks; Dwight A Bellinger; Roland W Herzog; Paul E Monahan
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 5.  Animal models of hemophilia and related bleeding disorders.

Authors:  Jay N Lozier; Timothy C Nichols
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

6.  Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.

Authors:  Matthew P Kosloski; Dipak S Pisal; Donald E Mager; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2013-04-25       Impact factor: 3.534

7.  Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.

Authors:  Atsushi Muto; Kazutaka Yoshihashi; Minako Takeda; Takehisa Kitazawa; Tetsuhiro Soeda; Tomoyuki Igawa; Zenjiro Sampei; Taichi Kuramochi; Akihisa Sakamoto; Kenta Haraya; Kenji Adachi; Yoshiki Kawabe; Keiji Nogami; Midori Shima; Kunihiro Hattori
Journal:  Blood       Date:  2014-10-01       Impact factor: 22.113

8.  Engineered Hematopoietic Stem Cells as Therapeutics for Hemophilia A.

Authors:  Philip M Zakas; H Trent Spencer; Christopher B Doering
Journal:  J Genet Syndr Gene Ther       Date:  2011-11-16

9.  Gene-based FVIIa prophylaxis modulates the spontaneous bleeding phenotype of hemophilia A rats.

Authors:  Shannon M Zintner; Juliana C Small; Giulia Pavani; Lynn Dankner; Oscar A Marcos-Contreras; Phyllis A Gimotty; Mads Kjelgaard-Hansen; Bo Wiinberg; Paris Margaritis
Journal:  Blood Adv       Date:  2019-02-12

10.  FVIII activity following FVIII protein infusion or FVIII gene transfer predicts the bleeding risk in hemophilia A rats.

Authors:  Karin M Lövgren; Malte S Larsen; Shannon M Zintner; Juliana C Small; Mads Kjelgaard-Hansen; Mattias Häger; Maj Petersen; Bo Wiinberg; Paris Margaritis
Journal:  J Thromb Haemost       Date:  2020-04-16       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.